Abstract:OBJECTIVE:To observe the effect of cisplatin alone or combined with anti-programmed death ligand 1 monoclonal antibody (anti-PD-L1 mAb) on the co-culture system of lung adenocarcinoma SPCA-1 cells and T lymphocytes, and therefore to study the immunotherapeutic effect of anti-PD-L1 mAb on lung cancer.METHODS:Human adenocarcinoma SPCA-1 cell line was selected by flow cytometry (FCM) due to its high expression of membranous programmed death ligand-1 (PD-L1). The concentration of cisplatin was determined by CCK-8 method depending on the inhibition rate of SPCA-1 cell, which was set to less-than-or-equal-to 20% (IC20). After treatment with different concentrations of cisplatin, cell proliferation (A value) of SPCA-1 cells and T lymphocytes were detected by CCK-8 method and cell cycle of SPCA-1 cells and cell apoptosis of T lymphocytes were analyzed using PI staining. Treated with different concentrations of cisplatin alone or in combination with anti-PD-L1, T lymphocyte proliferation in co-culture system was determined by CCK-8 method, and cytokines such as IFN (interferon)-γ, IL-2, IL-10 and TNF-α were detected with enzyme linked immunosorbent assay (ELISA) method.RESULTS:The IC20 of cisplatin on SPCA-1 cells was ≤ 0.78 mg/L. The proliferation of SPCA-1 cells were inhibited with different concentrations of cisplatin in a concentration-dependent manner (0.78∼12.5 mg/L) (P < 0.001). Compared with the group treated with high-dose of cisplatin (12.5 mg/L), the proliferation of T lymphocytes treated with low-dose of cisplatin (0.78 mg/L) was higher (t = 3.508, P < 0.05) and the number of late apoptotic and dead T lymphocytes in the co-culture system was reduced (t = 17.55, P < 0.001). Compared with the group of co-culture system, cisplatin (0.78 mg/L) combined with anti-PD-L1 (1.5 mg/L) significantly enhanced the proliferation of T lymphocytes in the co-culture system (t = 4.419, P < 0.01). Also, the levels of T helper cell type-1 (Th1) cytokines such as IFN-γ, IL-2 and TNF-α were up-regulated (t = 25.79-55.15, P < 0.01) and the T helper cell type-2 (Th2) cytokine IL-10 was down-regulated (t = 18.38, P < 0.01).CONCLUSION:Low-dose of cisplatin combined with anti-PD-L1 could effectively promote the proliferation of T lymphocytes in the microenvironment and increase the secretion of Th1 type cytokines. This may reduce the toxic effect of high-dose antineoplastic agents on immune cells and help eradication of tumor cells.

Combination of Low-Dose Cisplatin and Recombinant Porcine-Endoglin Induces Synergistic Antitumor Effects in Mice

Combination of Low‐dose Cisplatin and Recombinant Xenogeneic Endoglin As a Vaccine Induces Synergistic Antitumor Activities

Effect of Alarelin Combined with Cisplatin on Subcutaneous Xenograft of Human Endometrial Carcinoma in Nude Mice

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Ganoderma Lucidum Polysaccharides Combined with Low-Dose Cisplatin Inhibits Tumor Growth and Enhances the Immune Function of Tumor-Bearing Mice

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma

A Study on the Antitumor Mechanism of a Recombinant Porcine Endoglin Used As a Protein Vaccine in Mice

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer

he Synergistic Anti-tumor Efect of Endostatin on a Tumor-progression Murine Lung Cancer Model

Improved Therapeutic Effectiveness By Combining Recombinant Cxc Chemokine Ligand 10 With Cisplatin In Solid Tumors

Suppression of Lung Cancer in Murine Model: Treated by Combination of Recombinant Human Endostsatin Adenovirus with Low-Dose Cisplatin

MG132 Affects on the Nude Mice Transplanted Tumor Tissues of Ovarian Epithelial Carcinoma and the Relationship with Cisplatin Combination

Study of the Anti-tumor Effects of Interstitial Radiotherapy with 32P Glass Microspheres in Combination with Low Dose Cisplatin on Experimental Mice Solid Tumor S180

Synergistic anti-tumor activity of cetuximab combining with cisplatin in human nasopharyngeal carcinoma cells

Effect of Cisplatin Alone or Combined with Monoclonal Anti-Programmed Death Ligand-1 Anti-Body on Lung Adenocarcinoma Cell Line SPCA-1 and T Lymphocytes

Effect of Ginsenoside Rg3 Combined with Cisplatin on in Vivo Tumor in Liver Cancer Mice

Combination of Low Dose Cisplatin and Interstitial Injection of 32P Glass Microspheres Inhibits Tca8113 Cell Growth

Endostatin Enhances Antitumor Effect of Tumor Antigen-Pulsed Dendritic Cell Therapy in Mouse Xenograft Model of Lung Carcinoma

The Synergistic Anticancer Effect of Dual Drug- (Cisplatin/Epigallocatechin Gallate) Loaded Gelatin Nanoparticles for Lung Cancer Treatment